BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37214466)

  • 1. Hydroxychloroquine and azithromycin alter the contractility of living porcine heart slices.
    Wu Q; Ross AJ; Ipek T; Thompson GH; Johnson RD; Wu C; Camelliti P
    Front Pharmacol; 2023; 14():1127388. PubMed ID: 37214466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues.
    Wong AO; Gurung B; Wong WS; Mak SY; Tse WW; Li CM; Lieu DK; Costa KD; Li RA; Hajjar RJ
    J Mol Cell Cardiol; 2021 Apr; 153():106-110. PubMed ID: 33373642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.
    Khan AA; Khan Z
    Chem Biol Interact; 2020 Dec; 332():109299. PubMed ID: 33098839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.
    Özdemir İH; Özlek B; Özen MB; Gündüz R; Çetin N; Bilge AR
    Int J Clin Pract; 2021 Feb; 75(2):e13896. PubMed ID: 33280207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.
    Bakhshaliyev N; Özdemir R
    Ann Noninvasive Electrocardiol; 2021 Jul; 26(4):e12846. PubMed ID: 33956361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro safety "clinical trial" of the cardiac liability of drug polytherapy.
    Charrez B; Charwat V; Siemons B; Finsberg H; Miller EW; Edwards AG; Healy KE
    Clin Transl Sci; 2021 May; 14(3):1155-1165. PubMed ID: 33786981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Adverse Effects of Azithromycin and Hydroxychloroquine on Human Cardiomyocytes at a Clinically Relevant Treatment Duration.
    Li W; Luo X; Poetsch MS; Oertel R; Nichani K; Schneider M; Strano A; Hasse M; Steiner RP; Cyganek L; Hettwer K; Uhlig S; Simon K; Guan K; Schubert M
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
    O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
    JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying arrhythmic long QT effects of hydroxychloroquine and azithromycin with whole-heart optical mapping and simulations.
    Uzelac I; Kaboudian A; Iravanian S; Siles-Paredes JG; Gumbart JC; Ashikaga H; Bhatia N; Gilmour RF; Cherry EM; Fenton FH
    Heart Rhythm O2; 2021 Aug; 2(4):394-404. PubMed ID: 34430945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Safety "Clinical Trial" of the Cardiac Liability of Hydroxychloroquine and Azithromycin as COVID19 Polytherapy.
    Charrez B; Charwat V; Siemons B; Finsberg H; Miller E; Edwards AG; Healy KE
    bioRxiv; 2020 Dec; ():. PubMed ID: 33398282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases.
    Zhu X; Wang Y; Xiao Y; Gao Q; Gao L; Zhang W; Xin X; Chen K; Srivastava U; Ginjupalli VKM; Cupelli M; Lazzerini PE; Capecchi PL; Chen L; Boutjdir M
    Sci Rep; 2022 Jan; 12(1):1075. PubMed ID: 35058480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart Muscle Microphysiological System for Cardiac Liability Prediction of Repurposed COVID-19 Therapeutics.
    Charrez B; Charwat V; Siemons BA; Goswami I; Sakolish C; Luo YS; Finsberg H; Edwards AG; Miller EW; Rusyn I; Healy KE
    Front Pharmacol; 2021; 12():684252. PubMed ID: 34421592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study.
    Huang HD; Jneid H; Aziz M; Ravi V; Sharma PS; Larsen T; Chatterjee N; Saour B; Aziz Z; Nayak H; Trohman RG; Krishnan K
    Cardiol Ther; 2020 Dec; 9(2):523-534. PubMed ID: 33058086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case.
    Montnach J; Baró I; Charpentier F; De Waard M; Loussouarn G
    Europace; 2021 Jul; 23(7):1124-1133. PubMed ID: 34009333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment.
    Ghazy RM; Almaghraby A; Shaaban R; Kamal A; Beshir H; Moursi A; Ramadan A; Taha SHN
    Sci Rep; 2020 Dec; 10(1):22139. PubMed ID: 33335141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Sarayani A; Cicali B; Henriksen CH; Brown JD
    Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
    Shah RR
    J Clin Pharm Ther; 2021 Feb; 46(1):17-27. PubMed ID: 32981089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients.
    Bakhshaliyev N; Uluganyan M; Enhos A; Karacop E; Ozdemir R
    J Electrocardiol; 2020; 62():59-64. PubMed ID: 32827987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial.
    Ried K; BinJemain T; Sali A
    Cureus; 2021 Nov; 13(11):e19902. PubMed ID: 34976511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
    Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
    Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.